ClinicalTrials.gg
CompletedNCT02977065Updated Nov 6, 2018

To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors

A Phase 2 interventional study of Atorvastatin 20mg and Atorvastatin 20 mg + CKD-519 50 mg in Dyslipidemias, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Australia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-06.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Enrollment
36th of 47
62 · median 165
Started
2017
with 2 others
Phase 2
8 of 47
none open now
Registered
36th of 47
by date
Lead sponsor
3 of 47
Chong Kun Dang Pharmaceutical

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 36th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 2, and was the 36th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or rosuvastatin in subjects with dyslipidemia.

Read the detailed description

The purpose of this study is to assess the safety, efficacy, and tolerability of CKD-519, administered with HMG-CoA reductase inhibitors in subjects with dyslipidemia

03

Conditions studied

  • Dyslipidemias

Keywords

  • Dyslipidemia
  • CETP Inhibitors
  • Hyperlipidemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 80 years.
  2. Dyslipidemia with LDL-C

    • At screening if untreated: 100 to 190 mg/dL
    • At screening if treated with statins or other lipid-lowering drugs: 100 to 170 mg/dL
    • At start of double-blind treatment: 100 to 190 mg/dL.
  3. HDL-C \<45 mg/dL (males) or \<50 mg/dL (females).
  4. Fasting TG \<400 mg/dL.
  5. Presence of the following conditions is permitted but not mandatory, at the discretion of the investigator:

    • Treated and stable coronary heart disease without acute events in the past 3 months and stable, state-of-the-art medication.
    • Treated and stable carotid artery disease or peripheral arterial disease on stable, standard medication for the past 3 months
    • Treated and stable Type 2 diabetes mellitus with glycosylated () ≤9.5%.
  6. Willing and able to sign the form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Chronic heart failure as defined by classes III and IV.
  2. Uncontrolled cardiac arrhythmias.
  3. Myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, or unstable angina in past 3 months before Visit 1.
  4. Stroke or within 3 months before Visit 1.
  5. Uncontrolled hypertension.
  6. laboratory abnormalities

    • or alanine aminotransferase >2 times
    • >1.5 times upper limit of normal range
    • Creatine kinase >2 times upper limit of normal range.
  7. Any active nephropathy or estimated \<60 mL/min/1.73m2 or on kidney dialysis.
  8. Poorly controlled (thyroid-stimulating hormone [TSH] >2 times upper limit of normal) hyperthyroidism.
  9. Homozygous familial hypercholesterolemia.
  10. Intolerance or to atorvastatin or rosuvastatin.
  11. Prior treatment with any CETP inhibitor.
  12. Positive for (HIV) positive, or .
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    Atorvastatin 20 mg

    To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks

    Drug: Atorvastatin 20mg

  • Experimental
    Atorvastatin 20 mg + CKD-519 50 mg

    To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks

    Drug: Atorvastatin 20 mg + CKD-519 50 mg

  • Experimental
    Atorvastatin 20 mg + CKD-519 100 mg

    To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks

    Drug: Atorvastatin 20 mg + CKD-519 100 mg

  • Experimental
    Atorvastatin 20 mg + CKD-519 200 mg

    To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks

    Drug: Atorvastatin 20 mg + CKD-519 200 mg

  • Active comparator
    Rosuvastatin 10 mg

    To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks

    Drug: Rosuvastatin 10 mg

  • Experimental
    Rosuvastatin 10 mg + CKD-519 100 mg

    To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks

    Drug: Rosuvastatin 10 mg + CKD-519 100 mg

Interventions

  • PO daily for 4weeks

    Also known as: Lipitor 20mg

  • DrugAtorvastatin 20 mg + CKD-519 50 mg

    Drug page: Atorvastatin

    PO daily for 4weeks

    Also known as: Lipitor 20mg

  • DrugAtorvastatin 20 mg + CKD-519 100 mg

    Drug page: Atorvastatin

    PO daily for 4weeks

    Also known as: Lipitor 20mg

  • DrugAtorvastatin 20 mg + CKD-519 200 mg

    Drug page: Atorvastatin

    PO daily for 4weeks

    Also known as: Lipitor 20mg

  • PO daily for 4weeks

    Also known as: Crestor 10mg

  • DrugRosuvastatin 10 mg + CKD-519 100 mg

    Drug page: Rosuvastatin

    PO daily for 4weeks

    Also known as: Crestor 10mg

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline (Visit 3) in LDL-C

    Time frame: at Week 4

Secondary outcomes

  1. Percentage change from baseline in HDL-C

    Time frame: at Weeks 2 and Week 4

  2. Percentage change from baseline in concentration of HDL particles (HDL-P)

    Time frame: at Weeks 2 and 4

  3. Change from baseline in size of HDL particles (HDL-P)

    Time frame: at Weeks 2 and 4

  4. Percentage change from baseline in LDL-C

    Time frame: at Week 2

  5. Change in concentration from baseline in LDL-C

    Time frame: at Weeks 2 and 4

  6. Change in concentration from baseline in HDL-C

    Time frame: at Weeks 2 and 4

  7. Percentage change from baseline in total cholesterol, TG, and non-HDL-C

    Time frame: at Weeks 2 and 4

  8. Change in concentration from baseline in total cholesterol, TG, and non-HDL-C

    Time frame: at Weeks 2 and 4

  9. Percentage change from baseline in apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1), and apolipoprotein E (Apo E)

    Time frame: at Weeks 2 and 4

  10. Change in concentration from baseline in Apo B, Apo A1, and Apo E

    Time frame: at Weeks 2 and 4

  11. Percentage change from baseline in lipoprotein(a) (Lp-a)

    Time frame: at Weeks 2 and 4

  12. Change in concentration from baseline in Lp-a

    Time frame: at Weeks 2 and 4

  13. Change in concentration from baseline in high-sensitivity C-reactive protein at

    Time frame: at Weeks 2 and 4

07

Study locations

1 site
  • Not provided
    Adelaide, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Dec 2017, 9 months.

Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2016
First posted
Nov 30, 2016
StartActual
Mar 23, 2017
Primary completionActual
Dec 30, 2017
CompletionActual
Jan 30, 2018
Last update
Nov 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02977065
Responsible party
Sponsor
First posted
Nov 30, 2016
Start date
Mar 23, 2017
Primary completion
Dec 30, 2017
Completion
Jan 30, 2018
Last update
Nov 6, 2018

Study contacts

Kyung-Mi Park, PhD
study director · Chong Kun Dang Pharm.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Rosuvastatin

Start the discussion